GlaxoSmithKline recently held a high-level scientific conference in conjunction with the launch of “Bexsero,” the first ...

GSK plc GSK announced that the U.S. Centers for Disease Control and Prevention’s (“CDC”) Advisory Committee on Immunization ...

Vaccine recommended to help protect persons ... Important Safety Information for BEXSERO in the US The following is based on the US Prescribing Information for BEXSERO. Please consult the full ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

Penmenvy combines the antigenic components of GSK’s approved Bexsero and Menveo meningococcal vaccines to target five common invasive meningococcal disease (IMD)-causing serotypes (A, B, C, W and Y).

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

The MenB vaccine (Bexsero and Trumenba) protects against type B. The CDC recommends that parents of preteens and teens talk ...

This second article in our series looking at some of the shortlisted candidates focuses on Novartis' meningococcal B vaccine Bexsero. Few infections will strike as much fear into a parent as ...

Thanks in part to research led by Bristol, the UK has played a leading role in the fight against the disease with its pioneering use of a vaccine – Bexsero – that is both effective at reducing cases ...

GSK announced two important endorsements from the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...

GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices: London, UK Saturday, April 19, 2025, 13:00 Hrs ...